Skip to main content

CSL Ltd Value Stock - Dividend - Research Selection


ISIN: AU000000CSL8 , WKN: 890952

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


CSL Limited: Positive Capital Return And Earnings Growth Expectations

CSL Limited is committed to allocating 10%-11% of its sales to R&D investments on a yearly basis. Read more to see why I am bullish on CSLLY stock.

CSL upgraded to Buy from Neutral at Goldman Sachs

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

CSL and uniQure Win 2023 Prix Galien USA Award

Global biotechnology leader CSL (ASX: CSL) and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the companies have received the 2023 Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases for HEMGENIX® (etranacogene dezaparvovec-drlb).

Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B

Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia B. HEMGENIX is indicated for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. There is no clinical experience of HEMGENIX use in patients with mild or moderate hemophilia B (FIX activity >2%).

Concurrent use of COVID and flu shots is linked to stroke risk in older adults

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

CSL Limited's (ASX:CSL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

With its stock down 9.7% over the past three months, it is easy to disregard CSL (ASX:CSL). However, stock prices are...

CSL (CMXHF) Gets a Buy from Macquarie

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics is leveraging strong volume growth in plasma collections, as well as growth in hospital hemostasis and venous closure. Explore more details here.

CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was awarded the contract after an extensive review of the energy market. The agreement will significantly advance CSL's Scope 1 & 2 emissions reductions with all electricity used by CSL's Australian manufacturing sites matched by renewable electricity certificates. The PPA includes a provision that gives preference

New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from three studies supporting the clinical, public health and economic value of both cell-based and adjuvanted seasonal influenza vaccines. The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 confe